Asterias Biotherapeutics Inc (AST) PT Set at $12.00 by HC Wainwright

HC Wainwright set a $12.00 price objective on Asterias Biotherapeutics Inc (NYSE:AST) in a research report sent to investors on Tuesday, July 11th. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on AST. Zacks Investment Research downgraded shares of Asterias Biotherapeutics from a buy rating to a hold rating in a research report on Monday, April 3rd. Laidlaw initiated coverage on shares of Asterias Biotherapeutics in a research note on Tuesday, April 4th. They set a buy rating and a $12.00 target price for the company.

Shares of Asterias Biotherapeutics (AST) traded up 3.17% during midday trading on Tuesday, hitting $3.25. 50,864 shares of the stock traded hands. The stock’s market cap is $160.10 million. Asterias Biotherapeutics has a one year low of $2.54 and a one year high of $5.80. The firm has a 50-day moving average price of $3.48 and a 200 day moving average price of $3.46.

TRADEMARK VIOLATION NOTICE: “Asterias Biotherapeutics Inc (AST) PT Set at $12.00 by HC Wainwright” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/11/asterias-biotherapeutics-inc-ast-given-a-12-00-price-target-at-hc-wainwright-updated-updated-updated.html.

An institutional investor recently raised its position in Asterias Biotherapeutics stock. Teachers Advisors LLC boosted its stake in Asterias Biotherapeutics Inc (NYSE:AST) by 13.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,028 shares of the biotechnology company’s stock after buying an additional 6,714 shares during the period. Teachers Advisors LLC owned approximately 0.12% of Asterias Biotherapeutics worth $206,000 at the end of the most recent quarter.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

What are top analysts saying about Asterias Biotherapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Asterias Biotherapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit